Peptide Nasal Sprays: Why Semax and Selank Are Preferred This Way
The nasal cavity offers something most drug delivery routes cannot: a direct pathway to the brain. For neuropeptides like Semax and Selank, this anatomical shortcut isn't just convenient — it's arguably essential to their pharmacological activity. Both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and have been prescribed intranasally in Russia for decades, yet their delivery mechanism remains underappreciated in Western research circles.
Understanding why these peptides are preferentially administered as nasal sprays requires a closer look at the blood-brain barrier, peptide degradation kinetics, and the unique neuroanatomy of the olfactory region.
The Blood-Brain Barrier Problem
Most peptides face a fundamental pharmacokinetic challenge: they cannot efficiently cross the blood-brain barrier (BBB). The BBB is a highly selective semipermeable border of endothelial cells that prevents most circulating molecules — especially hydrophilic, high-molecular-weight compounds — from entering the central nervous system.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, a synthetic analog of ACTH 4-10) has a molecular weight of approximately 813 Da. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, based on the endogenous peptide tuftsin) weighs roughly 751 Da. While these are relatively small peptides, their polar, charged amino acid residues make passive diffusion across the BBB extremely limited.
Pardridge, 2005 demonstrated that fewer than 2% of small-molecule drugs and virtually no large-molecule drugs cross the BBB via lipid-mediated free diffusion. For peptide-based neurotropics, this creates a clear bottleneck: even if the peptide reaches systemic circulation, only a negligible fraction arrives at its CNS targets.
Nose-to-Brain Transport: Bypassing the Barrier
Intranasal delivery circumvents this problem through two primary pathways: the olfactory nerve pathway and the trigeminal nerve pathway. Both allow molecules deposited in the upper nasal cavity to travel directly into the brain without entering systemic circulation first.
The olfactory epithelium, located in the roof of the nasal cavity, contains bipolar neurons whose dendrites extend into the nasal mucosa while their axons project directly through the cribriform plate into the olfactory bulb. Molecules absorbed at this site can undergo intracellular or extracellular transport along these neurons into the CNS within minutes.
Lochhead and Thorne, 2012 provided a comprehensive review demonstrating that intranasal delivery can achieve brain concentrations of peptides that are orders of magnitude higher than equivalent systemic doses. The trigeminal pathway offers a secondary route, delivering compounds to the brainstem and pons regions.
Dhuria et al., 2010 further confirmed that intranasally administered peptides appear in cerebrospinal fluid and brain tissue at concentrations that cannot be explained by systemic absorption alone, providing strong evidence for direct nose-to-brain transport.
Semax: Optimized for Intranasal Delivery
Semax was specifically designed and formulated for intranasal administration. Its primary researched effects — neuroprotection, cognitive enhancement, and modulation of BDNF expression — all require central activity.
Research by Dolotov et al., 2006 showed that intranasal Semax administration significantly increased BDNF and its receptor trkB mRNA expression in the rat hippocampus and cortex. These neurotrophic effects are critical to the peptide's proposed mechanism and would be largely lost with peripheral-only delivery.
A key pharmacokinetic study by Shevchenko et al., 2019 demonstrated that Semax reaches the brain within minutes of intranasal administration, with detectable concentrations in the hippocampus, hypothalamus, and cerebellum. The study used radiolabeled Semax and confirmed direct transport via olfactory and trigeminal pathways.
Clinical research in Russia has used intranasal Semax at concentrations of 0.1% and 1% solutions for conditions including:
Ashmarin et al., 1995 published early clinical findings showing that intranasal Semax improved memory and attention parameters in human subjects, establishing the nasal route as the standard delivery method for subsequent research.
Selank: Anxiolytic Effects Require Central Access
Selank, a synthetic analog of the immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for metabolic stability, presents a dual-action profile: peripheral immunomodulation and central anxiolytic effects. While its immune effects can be mediated systemically, the anxiolytic properties depend on CNS penetration.
Kozlovskii and Danchev, 2003 demonstrated that Selank exhibits anxiolytic activity comparable to benzodiazepines in animal models, but without the sedative, amnestic, or dependence-producing side effects. These effects are mediated through GABAergic modulation and enkephalin metabolism in the brain — processes that require the peptide to reach central targets.
Research by Semenova et al., 2009 found that intranasal Selank altered the expression of 73 genes in the hippocampus, including those involved in GABAergic neurotransmission, serotonin transport, and inflammatory signaling. This broad transcriptomic effect in a specific brain region underscores why direct CNS delivery matters.
Selank is typically administered intranasally at a 0.15% concentration, with research protocols using doses in the range of 250–500 µg per administration.
Why Not Subcutaneous Injection?
Researchers sometimes ask whether subcutaneous injection — the standard route for many research peptides — could substitute for nasal delivery. For Semax and Selank, the answer is nuanced.
Subcutaneous injection does deliver peptides into systemic circulation efficiently, but several factors work against it for these specific compounds:
The Pro-Gly-Pro C-terminal modification in both peptides does improve metabolic stability somewhat, but not enough to overcome the fundamental delivery challenge. Potaman et al., 1991 characterized the degradation pathways of Semax and showed that the PGP motif extends half-life compared to native ACTH 4-10, but intranasal delivery remains necessary for reliable CNS effects.
Optimizing Nasal Spray Delivery
Not all nasal administration is equally effective. Research suggests several factors influence nose-to-brain transport efficiency:
Djupesland, 2013 published an extensive review of nasal drug delivery optimization, noting that conventional spray pumps deposit only about 5-10% of their payload in the olfactory region. This suggests that even with intranasal administration, delivery efficiency has substantial room for improvement.
Emerging Research Directions
Several groups are investigating enhanced formulations for intranasal neuropeptide delivery. Mucoadhesive polymers, absorption enhancers like chitosan, and nanoparticle carriers have all shown promise in improving nasal peptide bioavailability.
Illum, 2012 demonstrated that chitosan-based formulations can increase nasal peptide absorption by 3-5 fold compared to simple aqueous solutions. Whether such technologies will be applied to Semax or Selank formulations in future research remains to be seen.
The growing interest in intranasal peptide delivery extends well beyond these two compounds. Insulin, oxytocin, orexin, and various neurotrophic factors are all being investigated via this route — each benefiting from the same nose-to-brain anatomical advantage.